This is a randomized, double-blind, multicenter, parallel-groups, placebo controlled clinical trial for subjects with refractory complex partial onset seizures. Those eligible to participate are those who have completed their presurgical evaluation, and have had focal-onset seizures confirmed. Subjects will have felbamate or placebo added to their existing anticonvulsive regimen to determine whether adding felbamate will extend the time between seizures.
Showing the most recent 10 out of 65 publications